Dartigeas, Caroline
Slama, Borhane
Doyle, Margaret
Tapprich, Christoph
Albrecht, Claire
Dupuis, Sandrine
Wapenaar, Robert
Schmidt-Hieber, Charlotte
Leblond, Veronique
Clinical trials referenced in this document:
Documents that mention this clinical trial
FIRE Study: Real-World Effectiveness and Safety of Ibrutinib in Clinical Practice in Patients with CLL and MCL
https://doi.org/10.1007/s44228-022-00015-5
Article History
Received: 22 December 2021
Accepted: 15 March 2022
First Online: 14 September 2022
Declarations
:
: CD served on AbbVie, AstraZeneca, BeiGene, and Janssen advisory boards, and received travel grants from AbbVie, AstraZeneca, and Janssen. MD, CT, CA, and RW are employees of Janssen and report stock ownership of Johnson & Johnson. SD is an employee of Janssen. VL has received honoraria from AbbVie, Amgen, BeiGene, Gilead, Janssen, and Roche, and consultancy fees from AbbVie, AstraZeneca, BeiGene, Ely Lilly, Gilead, and Janssen, and research funding from AbbVie, Janssen, and Roche. BS and CS-H have nothing to disclose.
: This study was conducted in accordance with the principles stated in the Declaration of Helsinki. Informed consent was obtained from all patients prior to participating in the study.
: Not applicable.